McKesson (NYSE: MCK) was downgraded by Auriga from a “buy” rating to a “hold” rating in a research note issued on Tuesday. They currently have a $98.00 price target on the stock, up from their previous price target of $95.00.
Other equities research analysts have also recently issued reports about the stock. Analysts at Raymond James (NYSE: RJF) downgraded shares of McKesson from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday. Separately, analysts at Citigroup (NYSE: C) raised their price target on shares of McKesson to $102.00 in a research note to investors on Friday, March 30th. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs (NYSE: GS) raised their EPS on shares of McKesson in a research note to investors on Tuesday, March 27th. They now have a “buy” rating on the stock.
McKesson opened at 90.44 on Tuesday. McKesson has a 52-week low of $66.61 and a 52-week high of $92.69. The company has a market cap of $22.258 billion and a price-to-earnings ratio of 17.64.
The company last announced its quarterly results on Monday, April 30th. It reported $2.09 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $2.04 EPS by $0.05. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Analysts expect that McKesson will post $1.80 EPS next quarter.
McKesson Corporation (McKesson) provides medicines, pharmaceutical supplies, information and care management products and services across the healthcare industry.